BOB体育

A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.

Investigators

Laura Jacobsen, Michael J Haller

Status

Accepting Candidates

Ages

12 Years - 35 Years

Sexes

All

The study is a two-arm, multicenter, double-blinded clinical trial testing sequential therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr alone in new onset T1D. The primary objective is to test whether the C-peptide response to鈥�

Investigators

Laura Jacobsen, Michael J Haller

Status

Accepting Candidates

Ages

8 Years - 45 Years

Sexes

All